Exchange Traded Concepts, LLC Cellectis S.A. Transaction History

Exchange Traded Concepts, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 26, 2022	SELL	$3.45 - $8.77 $1.2 Million - $3.04 Million	-347,174 Closed	0 $0
Q4 2021 Jan 13, 2022	BUY	$8.01 - $12.84 $893,843 - $1.43 Million	111,591 Added 47.37%	347,174 $2.82 Million
Q3 2021 Oct 18, 2021	BUY	$11.94 - $16.09 $161,213 - $217,247	13,502 Added 6.08%	235,583 $2.97 Million
Q2 2021 Jul 30, 2021	BUY	$14.36 - $20.93 $857,837 - $1.25 Million	59,738 Added 36.8%	222,081 $3.44 Million
Q1 2021 Apr 20, 2021	BUY	$18.19 - $33.25 $1.88 Million - $3.43 Million	103,279 Added 174.86%	162,343 $3.28 Million
Q4 2020 Jan 19, 2021	BUY	$15.87 - $31.64 $280,375 - $558,983	17,667 Added 42.68%	59,064 $1.6 Million
Q3 2020 Oct 30, 2020	BUY	$15.7 - $20.84 $289,586 - $384,393	18,445 Added 80.36%	41,397 $766,000
Q2 2020 Jul 15, 2020	BUY	$8.21 - $21.02 $188,435 - $482,451	22,952 New	22,952 $409,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Exchange Traded Concepts, LLC, based on Form 13F filings with the SEC.

Stay updated on Exchange Traded Concepts, LLC with notifications on news.